Safety and Dosimetry of a New Radiotracer to Detect Misfolded SOD1 Associated With Amyotrophic Lateral Sclerosis
Status:
Recruiting
Trial end date:
2024-07-31
Target enrollment:
Participant gender:
Summary
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease, is a rare
neurodegenerative disease resulting in loss, primarily, of the motor neurons in the motor
cortex, brainstem and spinal cord. It currently affects 3 of every 100,000 people in the US.
Currently, there is no diagnostic tool for ALS, resulting in misdiagnosis and significant
disease progression before formal diagnosis. An imaging test for early detection of ALS and
for monitoring disease progression would have significant diagnostic and prognostic value.
PET imaging with an appropriate radiotracer has great potential as a biomarker for ALS given
that it would permit visualization of central nervous system (CNS) pathology in individuals
living with the disease.
To that extent, the primary goal of this phase I study is evaluating the safety and
biodistribution of the new tracer [89Zr]Zr-DFO-AP-101 in healthy volunteers and ALS patients.
Phase:
Phase 1
Details
Lead Sponsor:
Université de Sherbrooke
Collaborators:
AL-S Pharma AG Chorus Wellness Inc. Eli Lilly and Company